Genmab
CPSE:GMAB Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 78 Fair Values set on narratives written by author
WA
Consensus Narrative from 16 Analysts
EPKINLY's Global Approvals And Profound Bio Acquisition Will Strengthen Future Oncology Pipeline
Key Takeaways Genmab's focus on late-stage therapies, particularly EPKINLY, is expected to boost future revenue and growth due to best-in-class technology and market approvals. Acquisition of Profound Bio aims to expand innovative product offerings, enhancing long-term growth and revenue opportunities through advanced platforms.
View narrativeDKK 2.29k
FV
30.9% undervalued intrinsic discount17.42%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
19users have followed this narrative
23 days ago author updated this narrative